Elelyso
Gaucher Disease, Type 3
Ari ZimranPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Gaucher Disease, Type 3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eliglustat Sanofi | Phase 3 | BB |
Cerezyme Sanofi | Phase 3 | BB |
Venglustat Sanofi | Phase 3 | B |
Velaglucerase Alfa Shire | Phase 1/2 | CCC |
Arimoclomol ZevraDenmark | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Elelyso is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →